VCWA
MGRX icon

Vanguard Capital Wealth Advisors’s Mangoceuticals MGRX Stock Holding History

Vanguard Capital Wealth Advisors’s Portfolio MGRX Stock Details MGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,667
Closed -$6.92K – 163
2023
Q4 		$6.92K Hold
1,667
– – 0.01% 145
2023
Q3 		$21.3K Buy
+1,667
New +$31.2K 0.02% 132

Other funds holding MGRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
MCG
McCollum Christoferson Group Amherst, New York $341M AUM 15.01% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BL
BFSG LLC Irvine, California $1.13B AUM 29.95% 1-Year Est. Return

Vanguard Capital Wealth Advisors's MGRX Position: Q1 2024 in Review

Vanguard Capital Wealth Advisors sold out of Mangoceuticals (MGRX) in Q1 2024, closing a stake of 1,667 shares — an estimated $6.92K sold.

Vanguard Capital Wealth Advisors first reported a position in MGRX in Q3 2023 and held it in 2 quarters. The position peaked at $21.3K in Q3 2023. 8 funds tracked by Wall St. Rank hold MGRX as of Q1 2024.

  • Vanguard Capital Wealth Advisors reported no remaining Mangoceuticals position as of Q1 2024 after selling out during the quarter.
  • Vanguard Capital Wealth Advisors sold 1,667 Mangoceuticals shares in Q1 2024, an estimated $6.92K.
  • Vanguard Capital Wealth Advisors first reported a position in Mangoceuticals in Q3 2023 and held it in 2 quarters.
  • Vanguard Capital Wealth Advisors's Mangoceuticals position peaked at $21.3K in Q3 2023.
  • 8 funds tracked by Wall St. Rank held Mangoceuticals as of Q1 2024.

Based on Vanguard Capital Wealth Advisors's 13F filing for Q1 2024, filed 16 Apr 2024.